Ephedrine
Active ingredient · 5 therapeutic classes
- Drug class
- Adrenergic and Dopaminergic Agents
- Availability
- Prescription only
- Routes
- Intravenous, Intramuscular, Subcutaneous
- Markets covered
- 3
- Products on record
- 25
Overview
Plain-language summary, compiled from the cited regulatory records
Ephedrine sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent [1]. It belongs to the drug class of Adrenergic and Dopaminergic Agents [1].
This medication is approved for the treatment of clinically important hypotension that occurs during anesthesia [1].
Ephedrine is available in the market under various brand names [N].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 20 | April 24, 2026 |
| US United States | FDA | 2 | July 30, 2024 |
| CA Canada | Health Canada | 3 | March 22, 2025 |
GBUnited Kingdom· MHRA
20 products
Uses
Reversal of hypotension from spinal or epidural anaesthesia.
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. Ephedrine sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
( 1 )
How to take
CACanada· Health Canada
3 products
3 products on record with this regulator. Detailed label text (uses, dosage, side effects) is being ingested — the original document is linked under Sources [3].
Drug interactions
Known interactions involving Ephedrine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL015020103 · revised July 18, 2025
- [2]FDA DailyMed · 08f5ec19-7b53-68… · revised October 30, 2023 [PDF]
- [3]Health Canada (DPD) · 00876534 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.